Subscribe to Canada Free Press for FREE

Israeli human-on-a-chip platform has the unique ability to predict risk of toxicity in pharma and cosmetic product candidates without animal testing

Radical new drug-testing tech could dramatically cut animal testing


By —— Bio and Archives--August 2, 2017

Comments | Print Friendly | Subscribe | Email Us

After spending an average of $2.5 billion to develop a single new drug, sometimes pharma companies have to pull it from the market due to a bad outcome that was not detected in clinical studies.

That’s what happened in 2000, when a promising Type 2 diabetes drug called troglitazone led to idiosyncratic (unexplained) liver damage in one of every 60,000 users.

The troglitazone mystery wasn’t solved until March 2016, when a novel “liver-on-a-chip” platform developed by Hebrew University of Jerusalem Prof. Yaakov Nahmias revealed what no animal or human tests could: even low concentrations of this drug caused liver stress before any damage could be seen.

“It was the first time an organ-on-chip device could predict information to help pharmaceutical companies define risk for idiosyncratic toxicity,” Nahmias tells ISRAEL21c.—More…



ISRAEL21c -- Bio and Archives | Comments

ISRAEL21c was founded in 2001, in the wake of the Second Intifada, to broaden public understanding of Israel beyond typical portrayals in the mainstream media.

The organization’s founders – Israeli-American technology executives – understood the great power of the Internet and developed a first-of-its kind online product with global appeal and reach.

Commenting Policy

Please adhere to our commenting policy to avoid being banned. As a privately owned website, we reserve the right to remove any comment and ban any user at any time.

Comments that contain spam, advertising, vulgarity, threats of violence, racism, anti-Semitism, or personal or abusive attacks on other users may be removed and result in a ban.
-- Follow these instructions on registering: